The Urology Department is responsible for the medical and surgical treatment of pathologies associated with the male and female urinary tract and the male genitalia.
Its activities are essentially diagnosis and treatment and the monitoring of cancerous and non-cancerous conditions affecting the prostate, kidneys, bladder and male genitalia.
As our work is principally oncological in nature, we operate a strongly multidisciplinary approach to the treatment of all cancerous conditions associated with the genitourinary system.
Our team therefore works in close and constant collaboration with the Institut Bordet’s medical oncologists, radiotherapists, radiologists, nuclear medicine specialists and anatomopathologists.
The Institut Bordet Urology Department treats :
- prostate conditions:
- diagnosis of all prostate diseases
- treatment of benign prostate hypertrophia
- refinement (diagnosis) of prostate cancers via different examinations including biopsies conducted on an out-patient basis and under local anaesthesia
- hormone treatments
- surgical treatments mainly via robotic surgery
- focused ultrasound prostate treatment.
- Bladder conditions:
- treatment of incontinence problems (surgery, rehabilitation, urodynamic testing, etc)
- treatment of common bladder infections (for example, cystitis)
- diagnosis and treatment of bladder polyps (via fluorescent light)
- diagnosis and surgical treatment of malignant bladder tumours (cancers) with bladder reconstruction in cases of total organ ablation.
- Kidney and ureteral conditions:
- diagnosis and treatment of infectious diseases of the kidney (pyelonephritis, for example), renal calculi (kidney stones), etc.
- diagnosis and treatment of benign kidney tumours (cysts, for example)
- diagnosis and treatment of malignant tumours (cancers) of the kidney
- robotic surgery.
- Conditions affecting the male genitalia:
- diagnosis and treatment of cancerous and non-cancerous tumours of the penis and testicles
- laser treatment and sentinel node technique.
The Institut Bordet Urology Department is at the leading edge of fusion imaging, targeting and focused prostate cancer treatments (MRI – ultrasound – high frequency ultrasound).
Thanks to advances in medical imaging, in particular magnetic resonance imaging of the prostate, it is now possible to define suspect areas within the prostate. The Institut Bordet is the first centre to offer fusion imaging software. This software makes it possible to achieve very high precision guidance of the biopsies needed to characterise cancer. This fusion imaging is then exported in order to carry out focused treatment of the affected zones using high-energy ultrasound, thus allowing non-invasive, transrectal treatment of prostate cancer.
Head of Department
Dr A. Peltier
Dr G. Assenmacher
Prof. T. Roumeguère
Dr L. Demaeyer
Dr K. Mirzoyan
M. Requena Castro
External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Authors : Diamand R, Ploussard G, Roumiguié M, Oderda M, Benamran D, Fiard G, Quackels T, Assenmacher G, Simone G, van Damme J, Malavaud B, Iselin C, Descotes JL, Roche JB, Peltier A, Roumeguère T, Albisinni S
Year : 2020
Journal : Eur Urol
Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic.
Authors : Diamand R, Ploussard G, Roumiguié M, Oderda M, Benamran D, Fiard G, Peltier A, Simone G, van Damme J, Malavaud B, Iselin C, Descotes JL, Roche JB, Quackels T, Roumeguère T, Albisinni S
Year : 2020
Journal : World J Urol
Re: Jacques Beco and Jack Mouchel. Perineural dextrose injections in the treatment of lower urinary tract symptoms and dyspareunia induced by obturator neuralgia: Is it the pudendal nerve effect?
Authors : Aoun F, Mjaess G, Absil F, Bollens R
Year : 2020
Journal : Med Hypotheses
Volume : 143
Pages : 110131
Is there a role for repeating PSMA PET/CT after a negative scan in biochemical recurrent prostate cancer?
Authors : Mjaess G, Vierasu I, Lacroix S, Aoun F, Goldman S, Roumeguère T, Albisinni S
Year : 2020
Journal : Acta Oncol
Pages : 1-4
Evidence-based medicine, the number 'three' and its multiples in urological clinical rules.
Authors : Mjaess G, Aoun F, Albisinni S, Vanhaeverbeek M, Roumeguère T
Year : 2020
Journal : Scand J Urol
Pages : 1-3